- Home
- AGEN vs BWG Comparison
AGEN vs BWG Comparison
Compare AGEN & BWG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- BWG
- Stock Information
- Founded
- AGEN 1994
- BWG 2012
- Country
- AGEN United States
- BWG United States
- Employees
- AGEN N/A
- BWG N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- BWG Finance/Investors Services
- Sector
- AGEN Health Care
- BWG Finance
- Exchange
- AGEN Nasdaq
- BWG Nasdaq
- Market Cap
- AGEN 142.8M
- BWG 147.9M
- IPO Year
- AGEN 2000
- BWG N/A
- Fundamental
- Price
- AGEN $4.55
- BWG $8.91
- Analyst Decision
- AGEN Buy
- BWG
- Analyst Count
- AGEN 2
- BWG 0
- Target Price
- AGEN $14.50
- BWG N/A
- AVG Volume (30 Days)
- AGEN 395.5K
- BWG 53.8K
- Earning Date
- AGEN 11-11-2025
- BWG 01-01-0001
- Dividend Yield
- AGEN N/A
- BWG 11.37%
- EPS Growth
- AGEN N/A
- BWG N/A
- EPS
- AGEN N/A
- BWG N/A
- Revenue
- AGEN $101,706,000.00
- BWG N/A
- Revenue This Year
- AGEN $60.49
- BWG N/A
- Revenue Next Year
- AGEN N/A
- BWG N/A
- P/E Ratio
- AGEN N/A
- BWG N/A
- Revenue Growth
- AGEN N/A
- BWG N/A
- 52 Week Low
- AGEN $1.38
- BWG $6.86
- 52 Week High
- AGEN $7.34
- BWG $8.65
- Technical
- Relative Strength Index (RSI)
- AGEN 48.05
- BWG 72.10
- Support Level
- AGEN $4.36
- BWG $8.80
- Resistance Level
- AGEN $5.20
- BWG $8.86
- Average True Range (ATR)
- AGEN 0.27
- BWG 0.06
- MACD
- AGEN 0.04
- BWG 0.01
- Stochastic Oscillator
- AGEN 40.91
- BWG 93.55
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About BWG BrandywineGLOBAL Global Income Opportunities Fund Inc.
BrandywineGLOBAL - Global Income Opportunities Fund Inc is a non-diversified, closed-end management investment company. The primary investment objective is to provide current income. The secondary investment objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing, under normal market conditions, at least 80% of its assets in world-wide fixed-income securities.